ReMYND N.V.
Records under this name other than the patents ReMYND N.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Showing 1 to 10 of 10 · Back to ReMYND N.V.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,939,324 | Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,548,881 | Compounds for the Treatment of Epilepsy, Neurodegenerative Disorders and Other CNS Disorders Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,722,681 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases Lapsed on the fee record Ended May 13, 2026 · USPTO record | Lapsed on the fee record | Ended May 13, 2026 | USPTO record |
| US 8,618,138 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases Lapsed on the fee record Ended Dec 31, 2025 · USPTO record | Lapsed on the fee record | Ended Dec 31, 2025 | USPTO record |
| US 9,808,456 | Piperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease Lapsed on the fee record Ended Nov 7, 2025 · USPTO record | Lapsed on the fee record | Ended Nov 7, 2025 | USPTO record |
| US 8,541,406 | Thiadiazole derivatives for the treatment of neurodegenerative diseases Lapsed on the fee record Ended Sep 24, 2025 · USPTO record | Lapsed on the fee record | Ended Sep 24, 2025 | USPTO record |
| US 9,750,745 | 2,7-diazaspiro[3.5]nonane compounds Lapsed on the fee record Ended Sep 5, 2025 · USPTO record | Lapsed on the fee record | Ended Sep 5, 2025 | USPTO record |
| US 9,617,264 | 2,7-diazaspiro[3.5]nonane compounds Lapsed on the fee record Ended Apr 11, 2025 · USPTO record | Lapsed on the fee record | Ended Apr 11, 2025 | USPTO record |
| US 10,562,869 | Oxadiazole compounds Lapsed on the fee record Ended Feb 18, 2024 · USPTO record | Lapsed on the fee record | Ended Feb 18, 2024 | USPTO record |
| US 7,960,556 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases Lapsed on the fee record Ended Jun 14, 2019 · USPTO record | Lapsed on the fee record | Ended Jun 14, 2019 | USPTO record |